BI 764532
Boehringer Ingelheim
['tarlatamab', 'hpn328', 'sclc', 'lcsm,(-blcsm)', 'hpn328 ']
bi 764532 a novel dll3/cd3 igg- like bispecific t-cell (bite) engager in dll3 positive sclc, similar results to tarlatamab and hpn328 #asco2023 #lcsm 
Associate Head Oncology. Fundación Jiménez Díaz. IIS - FJD. Head of Thoracic Oncology & Clinical Trials. Professor  @UAM_Madrid previously @RoyalFreeNHS London